Activity Summary:
To further expand knowledge from the Talking HLH: Practical Insights for Diagnosing and Managing Adult HLH, presented by Drs. Sarah Nikiforow and Daniella Schwartz, HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Adult HLH Diagnostic and Management Algorithm
A visually structured, step-by-step clinical algorithm outlining the recommended approach to evaluating and managing suspected adult HLH.

Adult HLH Recognition and Diagnostic Quick-Reference Guide
A concise clinical reference tool summarizing early warning signs, key laboratory markers, and recommended first-line investigations for suspected adult HLH.

Clinical Slide Kit
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

Guideline & References
Links to key clinical guidelines, landmark publications, diagnostic frameworks, and educational resources related to adult HLH and hyperinflammatory syndromes

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Adult HLH is increasingly recognized as part of a broader hyperinflammatory spectrum, yet early diagnosis and management remain challenging in clinical practice. Because many adults present with nonspecific symptoms that overlap with sepsis, malignancy-associated inflammation, or autoimmune disease, timely recognition and treatment can be difficult.

This four-episode podcast series explores the full spectrum of adult HLH, from raising diagnostic suspicion to implementing contemporary treatment strategies. Through expert discussion and real-world clinical insights, Dr. Sarah Nikiforow and Dr. Daniella Schwartz aim to strengthen the ability to recognize HLH across diverse clinical settings, integrate biomarkers and prognostic indicators into clinical decision-making, and apply adult-specific management strategies, including emerging therapeutic options.

Activity Summary:
Adult HLH is increasingly recognized as part of a broader hyperinflammatory spectrum, yet early identification and management remain challenging in routine clinical practice. Many adult patients present with nonspecific symptoms that overlap with sepsis, malignancy-associated inflammation, or autoimmune disease, which can delay recognition and treatment.

In this series, Drs. Sarah Nikiforow and Daniella Schwartz explore the full spectrum of adult HLH, from diagnostic suspicion to modern treatment approaches. Through four episodes, this activity aims to strengthen the ability to recognize HLH across diverse clinical settings, integrate biomarkers and prognostic indicators into clinical decision-making, and apply adult-specific management strategies, including emerging therapeutic options.

Activity Summary:
Continue exploring a collection of downloadable resources designed to support learning and clinical application from our recent activity, From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026 with Dr. Robert Terkeltaub.

Available Resources:

Downloadable Slides
Review presentation slides with key data, visuals, and clinical insights.

Podcast Transcript
Download the transcript for convenient text-based review anytime.

References & Resources
A list of key studies, abstracts, and materials featured in the activity.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice.

From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026, this CME-accredited podcast explores how to approach these complex cases with greater clarity and confidence. Featuring expert insights and the latest clinical evidence, each episode dives into practical strategies across the continuum of gout care.

Listeners will hear discussions on advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted treatments, along with key considerations around safety, sequencing, and collaborative care. Through real-world examples and focused conversations, this series equips clinicians with actionable tools to personalize treatment, address therapeutic challenges, and improve long-term outcomes for patients living with uncontrolled gout.

Activity Summary:
Managing uncontrolled gout can be challenging, especially when patients continue to flare, struggle with comorbidities, or fail to respond as expected to standard therapy. As the understanding of gout evolves beyond hyperuricemia alone, clinicians are increasingly called upon to integrate immune mechanisms, real-world evidence, and new treatment options into everyday decision-making. Staying current requires not only awareness of emerging data, but also clarity on how to apply it in complex, real-world patients.

From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026 is a CME-accredited educational program designed to help clinicians navigate these challenges with confidence. This program brings together expert perspectives, recent clinical evidence, and practical insights across the continuum of gout care. Learners will explore advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted approaches, while also addressing safety, sequencing, and multidisciplinary coordination. Through focused discussion and clinically relevant examples, participants will gain actionable strategies to personalize care, overcome treatment inertia, and improve long-term management for patients living with uncontrolled gout.

Activity Summary:
Clinical care for myasthenia gravis is entering a period of meaningful progress, with growing opportunities to improve how the disease is diagnosed, assessed, and treated. Increased awareness of disease heterogeneity and the expanding use of standardized severity assessments are helping clinicians better define disease burden and guide management decisions.

In this 20-minute podcast episode, Dr. James Howard Jr. provides comprehensive coverage of key MG presentations, scientific symposia, posters, and abstracts presented at AAN 2026.

Activity Summary:
Myasthenia gravis care is advancing quickly, with new evidence shaping how clinicians approach disease assessment and treatment selection. At the same time, variability in presentation, delays in diagnosis, and uncertainty around integrating emerging therapies continue to create challenges in clinical practice. Clinicians need concise, practical education that translates evolving data into clear and actionable strategies that can be applied in real-world care.

This focused Clinical Clip from AAN 2026 features Dr James (Chip) Howard, a leading expert in myasthenia gravis, delivering a 20-minute update on the most clinically relevant advances presented in Chicago. Designed for efficiency and practical application, this program highlights how to incorporate emerging therapies into individualized treatment plans to support confident, evidence-based decision-making.

Activity Summary:
Gout remains the most common form of inflammatory arthritis in adults, yet it continues to be one of the most misunderstood and mismanaged chronic diseases in clinical practice. Despite clear treatment guidelines and a growing array of therapeutic options, a substantial proportion of patients experience persistent flares, disease progression, and comorbid complications due to clinical inertia, fragmented care, and limited provider awareness of emerging innovations. This podcast, presented by Dr. Robert Terkeltaub, seeks to modernize clinical approaches to gout, accelerate the adoption of new evidence and therapies, and ultimately improve the quality and consistency of care for a patient population long underserved by existing education.

Activity Summary:
Gout remains the most common form of inflammatory arthritis in adults, yet it continues to be one of the most misunderstood and mismanaged chronic diseases in clinical practice. Despite clear treatment guidelines and a growing array of therapeutic options, a substantial proportion of patients experience persistent flares, disease progression, and comorbid complications due to clinical inertia, fragmented care, and limited provider awareness of emerging innovations. This Lecture Library, presented by Dr. Robert Terkeltaub, seeks to modernize clinical approaches to gout, accelerate the adoption of new evidence and therapies, and ultimately improve the quality and consistency of care for a patient population long underserved by existing education.

Activity Summary:
Managing psoriasis (PsO) and psoriatic arthritis (PsA) presents multiple challenges for healthcare professionals, including staying up to date with emerging therapies, recognizing early signs of PsA, managing comorbidities, and implementing multidisciplinary care strategies. Despite advances in biologic and systemic therapies, unmet needs persist in timely diagnosis, patient education, and comprehensive disease management. Busy healthcare professionals often lack the time for in-depth study of the latest research, creating a critical need for concise, accessible educational opportunities. These unmet needs point to the necessity of practical, time-efficient programs that provide actionable insights into new treatment protocols and improve patient outcomes.

These podcast episodes are designed to provide healthcare professionals with an in-depth exploration of the most recent advances in the management of psoriasis (PsO) and psoriatic arthritis (PsA). The segments will focus on key challenges in clinical practice, including early diagnosis, personalized treatment strategies, and the integration of patient-reported outcomes. It will also address the management of associated comorbidities and the latest therapeutic developments, including biologics and small molecules.

Activity Summary:
Managing psoriasis (PsO) and psoriatic arthritis (PsA) presents multiple challenges for healthcare professionals, including staying up to date with emerging therapies, recognizing early signs of PsA, managing comorbidities, and implementing multidisciplinary care strategies. Despite advances in biologic and systemic therapies, unmet needs persist in timely diagnosis, patient education, and comprehensive disease management. Busy healthcare professionals often lack the time for in-depth study of the latest research, creating a critical need for concise, accessible educational opportunities. These unmet needs point to the necessity of practical, time-efficient programs that provide actionable insights into new treatment protocols and improve patient outcomes.

These Mini-Modules are designed to provide healthcare professionals with an in-depth exploration of the most recent advances in the management of psoriasis (PsO) and psoriatic arthritis (PsA). The segments will focus on key challenges in clinical practice, including early diagnosis, personalized treatment strategies, and the integration of patient-reported outcomes. It will also address the management of associated comorbidities and the latest therapeutic developments, including biologics and small molecules.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:
In this podcast series, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies.

Activity Summary:
Talking PsA is a podcast series that highlights the very latest clinical data in Psoriatic Arthritis. This activity includes management strategies and case-based topics to help clinicians select the most appropriate treatment, as well as address the significant health burdens and complications experienced by many patients during treatment.

Activity Summary:
In this webcast archive, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies.

Activity Summary:
Talking PsA is a webcast archive that highlights the very latest clinical data in Psoriatic Arthritis. Slides are developed and presented by leading Rheumatology and Dermatology experts and further reviewed and approved by the planning committee.

This activity includes case-based topics on management strategies for patients with PsA as well as clinical discussions by leading PsA experts.

Activity Summary:
Clinical Viewpoints HLH/MAS includes a curriculum that highlights the very latest clinical data in hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Slides are developed and updated throughout the year by leading HLH/MAS expert physicians. All content is reviewed and approved by the Clinical Viewpoints HLH/MAS Planning Committee.

The current initial treatment for hemophagocytic lymphohistiocytosis (HLH) and/or macrophage activation syndrome (MAS) aims to suppress the excessive activation of the immune system and treat the cytokine storm. However, contemporary HLH and MAS management is an evolving science that builds off each advance in basic/clinical research and clinical experience. This case-based slide kit discusses current controversies in the management of secondary HLH, including MAS.

Activity Summary:
The management of Psoriatic Arthritis (PsA) remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. Optimizing outcomes for PsA is dependent upon the early identifying patients, developing a personalized treatment strategy, and cohesively collaborating with a multidisciplinary team to address issues related to the challenges of diagnosis and access to appropriate therapy. Furthermore, research in PsA has evolved in recent years to reflect changes in the current disease landscape, study population, new management strategies, advanced recommendations on assessing patients’ overall disease activity and responses to treatment, healthcare providers’ and patients’ treatment expectations, and regulatory requirements. Understanding these can help guide clinical decision-making and improve outcomes for patients with PsA.

Talking PsA is an accredited AMA/ANCC/ACPE activity that highlights the very latest clinical data and is designed to optimize treatment strategies in PsA through a series of four patient case studies. The content and clinical cases were developed and presented by leading Rheumatology and Dermatology experts in PsA.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Patients seen in a typical rheumatology practice are at higher risk of PAH secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. Emerging evidence suggests that two of the most prevalent CTDs, systemic sclerosis (SSc) and systemic lupus erythematosus (SLE), should be regarded as separate diseases due to their different etiologies, prognoses, and therapeutic responses. This slide kit will present insights into the different pathophysiological processes and management of patients with SSc and SLE-PAH, as well as recommendations for routine screening, risk factors, diagnosis, management, and ongoing monitoring of patients in a rheumatology practice for PAH.

Activity Summary:
Clinical Viewpoints HLH includes a curriculum that highlights the very latest clinical data in Hemophagocytic Lymphohistiocytosis (HLH). Slides are developed and updated throughout the year by leading HLH expert physicians. The Lecture Library offers various topics that can be accessed for AMA or ANCC credit. Review the content and complete the pre- and post-tests and evaluation to receive your credit.

HLH is an aggressive and life-threatening syndrome of excessive immune activation. In persons with HLH, timely diagnosis and appropriate treatment are essential to achieving a successful outcome. This activity will utilize case-based scenarios to review the diverse clinical presentations of suspected HLH, time-efficient approaches for diagnosis, and considerations for targeted treatment and supportive management strategies. Continue to visit the Lecture Library series throughout 2022 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints HLH Planning Committee.

Activity Summary:
Talking PsA is a webcast archive that highlights the very latest clinical data in Psoriatic Arthritis. Slides are developed and presented by leading Rheumatology and Dermatology experts and further reviewed and approved by the planning committee.

This activity includes case-based topics on management strategies for patients with PsA as well as clinical discussions by leading PsA experts.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Patients seen in a typical rheumatology practice are at higher risk of PAH secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This lecture will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH.